BACKGROUND Bitter melon has been used to stop the growth of breast cancer(BRCA)cells.However,the underlying mechanism is still unclear.AIM To predict the therapeutic effect of bitter melon against BRCA using network p...BACKGROUND Bitter melon has been used to stop the growth of breast cancer(BRCA)cells.However,the underlying mechanism is still unclear.AIM To predict the therapeutic effect of bitter melon against BRCA using network pharmacology and to explore the underlying pharmacological mechanisms.METHODS The active ingredients of bitter melon and the related protein targets were taken from the Indian Medicinal Plants,Phytochemistry and Therapeutics and SuperPred databases,respectively.The GeneCards database has been searched for BRCA-related targets.Through an intersection of the drug’s targets and the disease’s objectives,prospective bitter melon anti-BRCA targets were discovered.Gene ontology and kyoto encyclopedia of genes and genomes enrichment analyses were carried out to comprehend the biological roles of the target proteins.The binding relationship between bitter melon’s active ingredients and the suggested target proteins was verified using molecular docking techniques.RESULTS Three key substances,momordicoside K,kaempferol,and quercetin,were identified as being important in mediating the putative anti-BRCA effects of bitter melon through the active ingredient-anti-BRCA target network study.Heat shock protein 90 AA,proto-oncogene tyrosine-protein kinase,and signal transducer and activator of transcription 3 were found to be the top three proteins in the proteinprotein interaction network study.The several pathways implicated in the anti-BRCA strategy for an active component include phosphatidylinositol 3-kinase/protein kinase B signaling,transcriptional dysregulation,axon guidance,calcium signaling,focal adhesion,janus kinase-signal transducer and activator of transcription signaling,cyclic adenosine monophosphate signaling,mammalian CONCLUSION Overall,the integration of network pharmacology,molecular docking,and functional enrichment analyses shed light on potential mechanisms underlying bitter melon’s ability to fight BRCA,implicating active ingredients and protein targets,as well as highlighting the major signaling pathways that may be altered by this natural product for therapeutic benefit.展开更多
文摘BACKGROUND Bitter melon has been used to stop the growth of breast cancer(BRCA)cells.However,the underlying mechanism is still unclear.AIM To predict the therapeutic effect of bitter melon against BRCA using network pharmacology and to explore the underlying pharmacological mechanisms.METHODS The active ingredients of bitter melon and the related protein targets were taken from the Indian Medicinal Plants,Phytochemistry and Therapeutics and SuperPred databases,respectively.The GeneCards database has been searched for BRCA-related targets.Through an intersection of the drug’s targets and the disease’s objectives,prospective bitter melon anti-BRCA targets were discovered.Gene ontology and kyoto encyclopedia of genes and genomes enrichment analyses were carried out to comprehend the biological roles of the target proteins.The binding relationship between bitter melon’s active ingredients and the suggested target proteins was verified using molecular docking techniques.RESULTS Three key substances,momordicoside K,kaempferol,and quercetin,were identified as being important in mediating the putative anti-BRCA effects of bitter melon through the active ingredient-anti-BRCA target network study.Heat shock protein 90 AA,proto-oncogene tyrosine-protein kinase,and signal transducer and activator of transcription 3 were found to be the top three proteins in the proteinprotein interaction network study.The several pathways implicated in the anti-BRCA strategy for an active component include phosphatidylinositol 3-kinase/protein kinase B signaling,transcriptional dysregulation,axon guidance,calcium signaling,focal adhesion,janus kinase-signal transducer and activator of transcription signaling,cyclic adenosine monophosphate signaling,mammalian CONCLUSION Overall,the integration of network pharmacology,molecular docking,and functional enrichment analyses shed light on potential mechanisms underlying bitter melon’s ability to fight BRCA,implicating active ingredients and protein targets,as well as highlighting the major signaling pathways that may be altered by this natural product for therapeutic benefit.
